Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History IMMP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics IMMP

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Immutep Ltd ADR

IMMP
Current price
1.69 USD +0.03 USD (+1.81%)
Last closed 1.68 USD
ISIN US45257L1089
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 250 361 504 USD
Yield for 12 month -15.50 %
1Y
3Y
5Y
10Y
15Y
IMMP
21.11.2021 - 28.11.2021

Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development. Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer. Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia. Address: Australia Square, Sydney, NSW, Australia, 2000

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

9.50 USD

P/E Ratio

Dividend Yield

Financials IMMP

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures IMMP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+2 516 796 USD

Last Year

+2 296 583 USD

Current Quarter

+2 062 025 USD

Last Quarter

+1 134 058 USD

Current Year

-24 700 275 USD

Last Year

+945 895 USD

Current Quarter

-14 531 979 USD

Last Quarter

-12 695 182 USD
EBITDA -48 739 236 USD
Operating Margin TTM -839.24 %
Price to Earnings
Return On Assets TTM -20.35 %
PEG Ratio
Return On Equity TTM -30.45 %
Wall Street Target Price 9.50 USD
Revenue TTM 4 878 805 USD
Book Value 0.12 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 49.10 %
Dividend Yield
Gross Profit TTM -41 562 124 USD
Earnings per share -0.21 USD
Diluted Eps TTM -0.21 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation IMMP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 7.65
Enterprise Value Revenue 803.42
Price Sales TTM 51.32
Enterprise Value EBITDA -2.94
Price Book MRQ 2.18

Technical Indicators IMMP

For 52 Weeks

1.32 USD 2.72 USD
50 Day MA 1.81 USD
Shares Short Prior Month 4 137 856
200 Day MA 1.91 USD
Short Ratio 32.35
Shares Short 4 185 716
Short Percent 2.93 %